

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

NALOX-1 PHARMACEUTICALS, LLC,
Petitioner,

v.

OPIANT PHARMACEUTICALS, INC.,
Patent Owner.

Case IPR2019-00690
Patent 9,468,747 B2

Before ERICA A. FRANKLIN, ZHENYU YANG,
and JACQUELINE T. HARLOW, *Administrative Patent Judges*.

YANG, *Administrative Patent Judge*.

DECISION
Denying Institution of *Inter Partes* Review
35 U.S.C. § 314(a)

INTRODUCTION

Nalox-1 Pharmaceuticals, LLC (“Petitioner”) filed a Petition (Paper 1 (“Pet.”)), seeking an *inter partes* review of claims 1–45 of U.S. Patent No. 9,468,747 B2 (“the ’747 patent,” Ex. 1001). Opiant Pharmaceuticals, Inc. (“Patent Owner”) filed a Preliminary Response. Paper 6 (“Prelim. Resp.”).

For the reasons provided below, we exercise our discretion under 35 U.S.C. § 314 to deny institution of an *inter partes* review.

Related Proceedings

Petitioner challenges claims 1–45 of the ’747 patent in two other concurrently filed petitions. In IPR2019-00688, Petitioner relies on Wyse¹ as the primary reference; and in IPR2019-00689, Petitioner relies on Wang² as the primary reference.

The ’747 patent is one of five patents listed in the Orange Book for intranasal naloxone sold under the brand name NARCAN. Pet. 1; Paper 9, 1. Petitioner also filed petitions for *inter partes* review, challenging the other four patents listed. Pet. 6; Paper 5, 1–2.

According to the parties, Patent Owner asserted all five Orange-Book-listed patents in *Adapt Pharma Operations Ltd. v. Teva Pharmaceuticals USA, Inc.*, Case 2:16-cv-07721 (D.N.J.) (consolidated, “the Teva Case”), and *Adapt Pharma Operations Ltd. v. Perrigo UK FINCO Limited*

¹ Wyse et al., U.S. Patent No. 9,192,570 B2, issued November 24, 2015 (Ex. 1007).

² Wang et al., Chinese Patent Publication No. CN 1575795 A, published February 9, 2005 (Ex. 1008).

Partnership, Case 2:18-cv-15287 (D.N.J.). Pet. 6; Paper 5, 2. Petitioner is not involved in those actions. Pet. 6.

Background of Technology and the '747 Patent

Opioid overdose is a crisis in the United States. Ex. 1001, 6:43. Naloxone is an opioid receptor antagonist that was initially approved for use by injection for the reversal of opioid overdose. *Id.* at 2:13–14. Naloxone hydrochloride injection prevents or reverses the effects of opioids, “including respiratory depression, sedation and hypotension.” Ex. 1044,³ 1300.

According to the '747 patent, administering naloxone via injection requires trained medical personnel and imposes the risk of exposure to blood borne pathogens through needlestick injury. Ex. 1001, 6:20–32. The '747 patent discloses that “it ha[d] been suggested that in view of the growing opioid overdose crisis in the US, naloxone should be made available over-the-counter (OTC), which would require a device, such as a nasal spray device, that untrained consumers are able to use safely.” *Id.* at 6:42–46.

The '747 patent acknowledges that nasal administration of naloxone was known and used by numerous medical services and health departments. Ex. 1001, 2:29–6:13, *see also id.* at 4:39–42 (“Overdose education and nasal naloxone distribution (OEND) programs are community-based interventions that educate people at risk for overdose and potential bystanders on how to prevent, recognize and respond to an overdose.”). It points out, however,

³ Physicians’ Desk Reference 2003, entry for NARCAN (Naloxone Hydrochloride Injection, USP).

although some studies “reported that the nasal administration of naloxone is as effective as the intravenous route in opiate addicts,” others “reported that naloxone administered intranasally displays a relative bioavailability of 4% only and concluded that the IN [intranasal] absorption is rapid but does not maintain measurable concentrations for more than an hour.” *Id.* at 2:47–55.

The ’747 patent states

Thus, there remains a need for durable, easy-to-use, needleless devices with storage-stable formulations, that can enable untrained individuals to quickly deliver a therapeutically effective dose of a rapid-acting opioid antagonist to an opioid overdose patient. The therapeutically effective dose should be sufficient to obviate the need for the untrained individual to administer either a second dose of opioid antagonist or an alternative medical intervention to the patient, and to stabilize the patient until professional medical care becomes available.

Id. at 6:52–61.

According to the ’747 patent, its invention relates to devices adapted for nasal delivery of “a therapeutically effective amount of an opioid antagonist selected from naloxone and pharmaceutically acceptable salts thereof, wherein the device is pre-primed, and wherein the therapeutically effective amount, is equivalent to about 2 mg to about 12 mg of naloxone hydrochloride.” *Id.* at 6:63–7:2.

Illustrative Claims

Among the challenged claims, claims 1 and 30 are independent, and are reproduced below:

1. A method of treatment of opioid overdose or a symptom thereof, comprising nasally administering to a patient in need thereof a dose of naloxone hydrochloride using a single-use, pre-primed device adapted for nasal delivery of a pharmaceutical composition to a patient by one actuation of said device into one nostril of said patient, having a single reservoir comprising a

pharmaceutical composition which is an aqueous solution of about 100 μ L comprising:

about 4 mg naloxone hydrochloride or a hydrate thereof;

between about 0.2 mg and about 1.2 mg of an isotonicity agent;

between about 0.005 mg and about 0.015 mg of a compound which is at least one of a preservative, a cationic surfactant, and a permeation enhancer;

between about 0.1 mg and about 0.5 mg of a stabilizing agent; and

an amount of an acid sufficient to achieve a pH of 3.5-5.5.

30. A pharmaceutical formulation for intranasal administration comprising, in an aqueous solution of not more than about 140 μ L:

about 4 mg naloxone hydrochloride or a hydrate thereof;

between about 0.2 mg and about 1.2 mg of an isotonicity agent;

between about 0.005 mg and about 0.015 mg of a compound which is at least one of a preservative, a cationic surfactant, and a permeation enhancer;

between about 0.1 mg and about 0.5 mg of a stabilizing agent;

an amount of an acid sufficient to achieve a pH of 3.5-5.5.

Asserted Grounds of Unpatentability

Petitioner challenges the patentability of claims 1–45 under 35 U.S.C.

§ 103 on the following grounds:

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.